Research

Driving Discovery Forward

We support high-impact research aimed at identifying and aggressively pursuing molecular, RNA, and genetic-based strategies for treating and curing GRIN2B Disorder.

Laboratory research

Strategy

Research pillars

We have adopted a comprehensive research strategy focused on exploring multiple avenues.

Drug repurposing

Investigating novel applications for approved medications to accelerate their rapid translation from research to clinical care.

Disease and animal modeling

We utilize advanced technologies, including human-derived organoids (mini-brains in a dish) and animal models, to better understand the disease and to test both pharmacological and genetic therapies.

Gene therapy

Correcting or compensating for the underlying genetic mutation in the GRIN2B gene. This can involve delivering a functional copy of the gene, modulating its expression, or repairing the mutation at the DNA or RNA level, with the goal of restoring normal NMDA receptor function and alleviating the neurological symptoms associated with the disorder.

Portfolio

The research we fund includes

  • Advanced 2D and 3D brain organoid models that allow for the precise testing of drug and gene therapies
  • Use of advanced techniques such as electrophysiology, 2-photon and digital holography imaging, and high-throughput screening methods to study the physiology and pathophysiology of NMDARs (N-methyl-D-aspartate receptors) and investigate synaptic plasticity
  • AAV therapy and cutting-edge systems using lipid nanoparticles to deliver the GRIN2B gene and/or RNA directly to affected neurons
  • Animal modeling to test how candidate therapies behave in a living nervous system, assessing efficacy, delivery and safety ahead of clinical work
  • RNA sequence analysis to identify the individual proteins and molecular pathways affected by GRIN2B pathogenic variants
  • Exploration of curative strategies including NMDA functionality, protein enhancement, RNA-based therapeutics, and gene replacement

Published work

Recent publications

Browse the scientific publications produced by our research network to learn how we’re advancing discoveries toward treatments and a cure.

Vectors and Use of Same in Genetic Treatment for NMDA Receptor–Related Encephalopathies

Patent: TRDF 2024093-00; US provisional application | GKF Ref: TECH-P-0306-USP

Click here →
Early maturation and hyperexcitability is a shared phenotype of cortical neurons derived from different ASD-associated mutations

July 06, 2023

Read here →
Two extreme Loss-of-Function GRIN2B-mutations are detrimental to tri-heteromeric NMDAR-function, but rescued by pregnanolone-sulfate

December 13, 2022

Read here →
Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy

Jul 2, 2021

Read here →